[
    [
        {
            "time": "",
            "original_text": "凯莱英：生物大分子CDMO业务板块计划在未来建设成为全球领先的开放式的、一体化生物制药能力和技术赋能平台",
            "features": {
                "keywords": [
                    "凯莱英",
                    "生物大分子",
                    "CDMO",
                    "业务板块",
                    "全球领先",
                    "开放式",
                    "一体化",
                    "生物制药",
                    "技术赋能平台"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "凯莱英：生物大分子CDMO业务板块计划在未来建设成为全球领先的开放式的、一体化生物制药能力和技术赋能平台",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]